|
|
|
|
|
|
|
|
Sponsored Links
|
 |
|
 |
|
Pharmacokinetics of Insulin
Preparations

|
|
Time
of Action |
|
Preparation |
Onset, h |
Peak, h |
Effective
Duration, h |
|
Short-acting, subcutaneous |
|
Lispro |
<0.25 |
0.51.5 |
34 |
|
Aspart |
<0.25 |
0.51.5 |
34 |
|
Glulisine |
<0.25 |
0.51.5 |
34 |
|
Regular |
0.51.0 |
23 |
46 |
|
Short-acting, inhaled |
|
Inhaled regular insulin |
<0.25 |
0.51.5 |
46 |
|
Long-acting |
|
NPH |
14 |
610 |
1016 |
|
Detemir |
14 |
a |
1220 |
|
Glargine |
14 |
a |
24 |
|
Insulin
Combinations |
|
75/2575% protamine lispro,
25% lispro |
<0.25 |
1.5 hb |
Up to
1016 |
|
70/3070% protamine aspart,
30% aspart |
<0.25 |
1.5 hb |
Up to
1016 |
|
50/5050% protamine lispro,
50% lispro |
<0.25 |
1.5 hb |
Up to
1016 |
|
70/3070% NPH, 30% regular
insulin |
0.51 |
Dual |
1016 |
|
50/5050% NPH, 50% regular
insulin |
0.51 |
Dual |
1016 |
aGlargine
has minimal peak activity;
detemir has some peak activity
at 614 h.
bDual:
two peaks; one at 23 h; the
second several hours later.
Related Criteria
Criteria for the Diagnosis of Diabetes Mellitus
More...
References:
-
Hirsch IB. Insulin
analogues.
N Engl J Med. 2005
Jan
13;352(2):174-83.
[Medline]
-
DeWitt DE, Hirsch
IB. Outpatient
insulin therapy in
type 1 and type 2
diabetes mellitus:
scientific review.
JAMA. 2003 May
7;289(17):2254-64.
[Medline]
Sponsored Links
|
|
|
Created: Dic 31, 2008 Last Modified:
01/22/2010
|
|
|
|